SCHEMBL30771272

SCHEMBL30771272

O=C(O)c1cncc2c(Br)c[nH]c12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.34
▸ HCAR2 Q8TDS4 1/20 0.34
▸ CSNK2A2 P19784 4/20 0.34
▸ CSNK2B P67870 4/20 0.34
▸ CSNK2A1 P68400 4/20 0.34
▸ KDM5A P29375 1/20 0.34
▸ KDM4C Q9H3R0 1/20 0.34
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.33
▸ TET2 Q6N021 1/20 0.32
▸ TET1 Q8NFU7 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.31
▸ HPGD P15428 1/20 0.31
▸ CCNT1 O60563 1/20 0.31
▸ PIM1 P11309 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ HASPIN Q8TF76 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20600200 0.76 CSNK2A1 (0.48) CSNK2A2CSNK2BCSNK2A1HTTCYP1A2
SCHEMBL30824209 0.76 CSNK2A1 (0.48) CSNK2A2CSNK2BCSNK2A1HTTCYP1A2
SCHEMBL10086124 0.74 HTT (0.54) CSNK2A2CSNK2BCSNK2A1HTTSMN1; SMN2
SCHEMBL22050219 0.70 CSNK2A2 (0.38) HCAR2CSNK2A2CSNK2BCSNK2A1KDM5A
SCHEMBL20111331 0.68 HCAR2 (0.46) POLBHCAR2KDM4CHTTCYP1A2
SCHEMBL659061 0.67 HCAR2 (0.42) POLBHCAR2KDM4CCYP1A2HSD17B10
SCHEMBL15334246 0.66 AKR1C3 (0.50) POLBHCAR2KDM4CKDM4EALDH1A1
SCHEMBL21749937 0.66 HCAR2 (0.41) POLBHCAR2KDM4CHSD17B10KDM4E
SCHEMBL20621866 0.65 HSD17B10 (0.42) CSNK2A2CSNK2BCSNK2A1HTTCYP1A2
SCHEMBL20621867 0.65 CCNC (0.36) CSNK2A2CSNK2BCSNK2A1HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 — — US disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 — — EP disclosed
CN-119173509-A ROCK inhibitors and uses thereof 迪哲(江苏)医药股份有限公司 2024-12-20 — — CN disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA POLB 4141/4885HCAR2 3363/4885CSNK2A2 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback